Therefore, regulation of Stat5 could constitute a new therapeutic approach, especially for postmenopausal osteoporosis and obesity-induced osteoporosis, since STAT5 plays a critical role in both adipocytes and osteoclasts. The gene discussed is STAT5A; the disease is obesity due to melanocortin 4 receptor deficiency.